Pfizer’s ADCETRIS combination regimen secures FDA approval for relapsed large B-cell lymphoma
The U.S. Food and Drug Administration (FDA) has approved Pfizer Inc.’s supplemental Biologics License Application (sBLA) for ADCETRIS (brentuximab vedotin) in combination with lenalidomide and ... Read More
Lyell Immunopharma to acquire ImmPACT—are CAR T-cell therapies the future of oncology?
Lyell Immunopharma is making waves with its strategic acquisition of ImmPACT Bio, a move aimed at bolstering its T-cell therapy capabilities. The transaction, valued at ... Read More